Loading
Nanobiotix
Nanobiotix is the Paris nanomedicine company behind NBTXR3, hafnium oxide nanoparticles injected into a tumour to make radiotherapy deposit more energy inside it.
Overview
Founded in 2003 and listed on Euronext Paris and Nasdaq, Nanobiotix built its business on the physics of radioenhancement: high atomic number nanoparticles that absorb X-rays and amplify the dose within the tumour. Its lead product NBTXR3 received a European CE mark for soft-tissue sarcoma in 2019 and is in the NANORAY-312 phase 3 trial in head and neck cancer, licensed to Johnson and Johnson in 2023.
Headquarters
Paris, France, FR
Scorecard
All companies#327of 1245 companies, score 12
- phase 3 +3
- modalities +2
- regions +1
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 0 targets, 10 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
2003
Products
1Phase 3Hafnium oxide nanoparticle radioenhancer, injected into the tumour
NBTXR3 is Nanobiotix's radioenhancer: a single injection of hafnium oxide nanoparticles that makes ordinary radiotherapy hit harder inside the tumour. It carries a European CE mark for soft-tissue sarcoma and is in a phase 3 trial in head and neck cancer with Johnson and Johnson.
Key papers
1Connected
7Similar pages
- TreatmentNimorazole
Shares Radiosensitisers, Head and neck squamous cell carcinoma and the tag radiation-wave3.
- TreatmentEvofosfamide
Shares Sarcomas (soft tissue, bone, GIST) and the tag radiation-wave3.
- TreatmentAvasopasem manganese
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
- TreatmentPilocarpine
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
- PersonSylvie Bonvalot
Shares Act.In.Sarc, NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial, Sarcomas (soft tissue, bone, GIST).
- TreatmentJNJ-90301900
Shares NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer, Head and neck squamous cell carcinoma.
- TrialBonner trial (cetuximab plus radiotherapy)
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
- TrialRTOG 91-11
Shares Radiosensitisers, Head and neck squamous cell carcinoma.
cancers
technologies
drugs
Phase 3Hafnium oxide nanoparticle radioenhancer, injected into the tumour
trials
key papers
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
nanobiotix.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Parent pages for breast, lung, leukaemia and biliary canc… · diff · file
Sourced, not expert-reviewed